Ginkgo Bioworks Balance Sheet
NYSE: DNAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ginkgo Bioworks financial position
At the end of fiscal 2025, Ginkgo Bioworks reported total assets of $1.12 billion, down 18.7% from a year earlier against total liabilities of $611.1 million. Shareholders' equity stood at $508.6 million, or 45.4% of assets. The company held $167.2 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 4.92, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Ginkgo Bioworks balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 167.20M | 561.57M | 944.07M | 1.32B | 1.55B | 380.80M | 495.29M |
| Short-Term Investments | 255.42M | 0 | — | — | — | — | — |
| Receivables | 24.03M | 21.86M | 17.16M | 80.91M | 131.54M | 16.69M | — |
| Inventory | — | — | 46.00K | 4.36M | 3.36M | 2.74M | — |
| Total Current Assets | 471.84M | 602.74M | 1.00B | 1.45B | 1.72B | 426.54M | — |
| Property, Plant & Equipment | 167.37M | 203.72M | 188.19M | 314.77M | 145.77M | 121.44M | — |
| Goodwill | — | 0 | 49.24M | 60.21M | 21.31M | 1.86M | 1.86M |
| Intangible Assets | 53.48M | 72.51M | 82.74M | 111.04M | 21.64M | 3.29M | — |
| Total Assets | 1.12B | 1.38B | 1.67B | 2.54B | 2.07B | 675.15M | — |
| Accounts Payable | 10.57M | 14.17M | 9.32M | 10.45M | 8.19M | 13.89M | — |
| Total Current Liabilities | 95.97M | 107.27M | 163.86M | 172.96M | 134.76M | 73.22M | — |
| Total Liabilities | 611.11M | 661.39M | 568.19M | 803.04M | 503.61M | 205.10M | — |
| Shareholders' Equity | 508.59M | 716.06M | 1.10B | 1.74B | 1.51B | 461.38M | 501.85M |
| Retained Earnings | -6.15B | -5.84B | -5.29B | -4.40B | -2.30B | -467.88M | — |
| Net Cash (Debt) | 422.62M | 561.57M | 944.07M | 1.32B | 1.55B | 380.80M | 495.29M |
| Shares Outstanding | 58.21M | 54.37M | 50.03M | 1.89B | 1.61B | 1.29B | — |
This table shows 7 annual periods of Ginkgo Bioworks's balance sheet, from FY 2025 back to FY 2019, across 16 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow DNA's reporting calendar. What is a balance sheet?